The ERα-dependency for the pro-survival action of E2 in GCT may explain the relatively limited clinical benefits of aromatase inhibitors, since not all GCT express ERα [31,136,139,140,141,142]. The gene discussed is CYP19A1; the disease is granular cell tumor.